Eledon Pharmaceuticals Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission File Number: 001-36620 ELEDON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) 20-1000967(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 19800 MacArthur Blvd., Suite 250Irvine, California(Address of principal executive offices) 92612(Zip Code) (949) 238-8090Registrant’s telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Smaller reporting company☒ Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No As of August 10, 2026 there were 81,261,152 shares of the Registrant’s common stock outstanding. Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined by the Private Securities LitigationReform Act of 1995, which statements involve substantial risks and uncertainties. Any statements other than statements ofhistorical or current fact in this Quarterly Report on Form 10-Q are forward-looking statements. In some instances, you can identifyforward-looking statements by the use of words such as “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,”“predicts,” “projects,” “targets,” “could,” “may,” “will,” and similar expressions, although not all forward-looking statementsinclude such identifying words. Forward-looking statements include, but are not limited to statements regarding: •our product development plans, expectations for and the timing of commencement, enrollment, completion, data, andrelease of results of clinical trials for our product candidates;•our expectations regarding the potential uses and efficacies of our product candidates;•our estimates regarding our liquidity, expenses, capital requirements and needs for additional financing;•our strategies with respect to our preclinical and clinical development programs, including our expectations regarding theproduction of clinical quantities of our product candidates;•our plans, strategy and timing to obtain and maintain regulatory approvals of our product candidates;•our expectations regarding competitive conditions for our product candidates; and•our expectations about our future financial performance or condition. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Reporton Form 10-Q, actual results may differ materially from those indicated by such forward-looking statements as a result of variousfactors, including the factors listed under “Risk Factor Summary” below. These risks and uncertainties, as well as other risks anduncertainties that could cause the Company’s actual results to differ significantly from the forward-looking statements containedherein, are described in greater detail in Part II, Item 1A.Risk Factorsin this Quarterly Report on Form 10-Q. Forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current beliefs, assumptions,expectations, estimates and projections, which may be impacted by known or unknown factors. Any forward-looking statementscontained in this Quarterly Report on Form 10-Q speak only as of the date hereof and not as of any future date, and the Companyexpressly disclaims any intent to update any forward-looking statements, whether